Celyad Oncology SA
XBRU:CYAD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2295
1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Celyad Oncology SA
Celyad Oncology SA
Other Liabilities
Celyad Oncology SA
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Other Liabilities
€6.1m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Other Liabilities
$40.3m
|
CAGR 3-Years
243%
|
CAGR 5-Years
93%
|
CAGR 10-Years
70%
|
|
|
Galapagos NV
AEX:GLPG
|
Other Liabilities
€986.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Oxurion NV
XBRU:OXUR
|
Other Liabilities
€159k
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celyad Oncology SA
Glance View
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
See Also
What is Celyad Oncology SA's Other Liabilities?
Other Liabilities
6.1m
EUR
Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Other Liabilities amounts to 6.1m EUR.
What is Celyad Oncology SA's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
-26%
Over the last year, the Other Liabilities growth was 30%. The average annual Other Liabilities growth rates for Celyad Oncology SA have been -36% over the past three years , -26% over the past five years .
You don't have any saved screeners yet
